Apogee Therapeutics (APGE) Enterprise Value (2022 - 2026)
Apogee Therapeutics (APGE) posted quarterly Enterprise Value of -$1.1 billion for Q1 2026, down 106.48% year-over-year from $16.4 billion in Q1 2025, and down 45.15% quarter-over-quarter from -$730.2 million in Q4 2025.
Apogee Therapeutics (APGE) Enterprise Value (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Enterprise Value for 5 consecutive years, with -$1.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 106.48% year-over-year to -$1.1 billion; the TTM figure through Mar 2026 stood at -$1.1 billion (down 106.48% YoY), while the FY2025 annual figure was -$730.2 million, down 40.25% from the prior year.
- Enterprise Value fell to -$1.1 billion in Q1 2026 per APGE's latest filing, from -$730.2 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$5.0 million in Q2 2022 and bottomed at -$1.1 billion in Q1 2026.
- Historically, Enterprise Value has averaged -$498.2 million across 5 years, with a median of -$517.0 million in 2024.
- Annual changes were most pronounced in 2023 — Enterprise Value plunged 2414.46% — and 2025, when it surged 37.11%.
- Apogee Therapeutics' Enterprise Value stood at -$151.9 million in 2022, then sank by 160.36% to -$395.5 million in 2023, then sank by 31.66% to -$520.7 million in 2024, then slumped by 40.25% to -$730.2 million in 2025, then plunged by 45.15% to -$1.1 billion in 2026.
- Business Quant data shows APGE's Enterprise Value at -$1.1 billion in Q1 2026, -$730.2 million in Q4 2025, and -$527.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | -971.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -971.97 Mn |
| Mar 31, 2026 | -1.06 Bn |
| Dec 31, 2025 | -730.19 Mn |
| Sep 30, 2025 | -527.29 Mn |
| Jun 30, 2025 | -505.39 Mn |
| Mar 31, 2025 | -513.32 Mn |
| Dec 31, 2024 | -520.65 Mn |
| Sep 30, 2024 | -526.08 Mn |
| Jun 30, 2024 | -676.20 Mn |
| Mar 31, 2024 | -816.20 Mn |
| Dec 31, 2023 | -395.46 Mn |
| Sep 30, 2023 | -422.85 Mn |
| Jun 30, 2023 | -125.07 Mn |
| Dec 31, 2022 | -151.89 Mn |
| Jun 30, 2022 | -4.97 Mn |